DUPIXENT

Phase 3Small molecule

Regeneron

DUPIXENT is one of 125 small molecule programs targeting Asthma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

124

Competitors

Pipeline

Status by Indication[3][1]

Indication

AsthmaUnknown

Chronic Rhinosinusitis With Nasal PolypsUnknown

Eosinophilic EsophagitisUnknown

Prurigo NodularisUnknown

COPDUnknown

Chronic RhinosinusitisActive, not recruiting

Atopic DermatitisRecruiting

AsthmaPreclinical

Unknown

Chronic Rhinosinusitis With Nasal PolypsPreclinical

Unknown

Eosinophilic EsophagitisPreclinical

Unknown

Prurigo NodularisPreclinical

Unknown

COPDPreclinical

Unknown

Chronic RhinosinusitisPreclinical

Active, not recruiting

Atopic DermatitisPhase 3

Recruiting

Competition

Competitive Landscape

175 competitors in Asthma

#DrugCompanyPhaseTrials

DUPIXENT

Regeneron

Phase 3

1 2

Celexa

AbbVie

Preclinical

1 3

Arcoxia

Novartis

Preclinical

—4

Solu-Medrol

MMassachusetts Eye and Ear Infirmary

Preclinical

1 5

Blood Withdrawn

Emergent BioSolutions

Preclinical

1 6

Paracetamol

GSK

Preclinical

1 7

Aclidinium Bromide

AstraZeneca

Preclinical

—8

Lexapro

SShirley Ryan AbilityLab

Preclinical

1 9

Blood Collection

AAssistance Publique - Hôpitaux de Paris

Preclinical

1 10

Biological Drug

UUniversitaire Ziekenhuizen KU Leuven

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Active, not recruiting

Chronic Rhinosinusitis With Nasal Polyposis

NCT04959448

Q2 2027

Post-ApprovalRecruiting

Nasal Polyps

NCT07268313

Q1 2028

Phase 3Not yet recruiting

Phase II

NCT07386743

Q2 2028

Phase 3Not yet recruiting

MPA

NCT06884891

Clinical

Trials by Indication[1]

Tics1 trial

A PhaseⅠ Comparative Study to Evaluate the Pharmacokinetics of QL2108 to Dupixent®

Completed· Qilu Pharmaceutical Co., Ltd. logo

Qilu Pharmaceutical Co., Ltd.·Phase 1·NCT06614907·198 enrolled

Atopic Dermatitis1 trial

Dupixent and Narrowband UVB for Atopic Dermatitis

Recruiting·PPsoriasis Treatment Center of Central New Jersey·Phase 4·NCT05285839·40 enrolled

Phase II1 trial

A Phase III Study of GS101 Injection to Dupixent®

Not yet recruiting·JJiangsu Genscend Biopharmaceutical Co., Ltd·Phase 3·NCT07386743·572 enrolled

Nasal Polyps1 trial

Complete Remission After Treatment With Biologics for Nasal Polyps

Recruiting·RRigshospitalet, Denmark·Phase 4·NCT07268313·66 enrolled

Asthma1 trial

Registry of Asthma Patients Initiating DUPIXENT®

Active, not recruiting· Regeneron logo

Regeneron··NCT04287621·718 enrolled

4 more indications

MPA1 trial

A Phase Ⅲ Comparative Study of QL2108 to Dupixent®

Not yet recruiting· Qilu Pharmaceutical Co., Ltd. logo

Qilu Pharmaceutical Co., Ltd.·Phase 3·NCT06884891·520 enrolled

Adult1 trial

A Multi-omics Disease Signature Trial in Adult Patients With Moderate to Severe AD

Completed· LEO Pharma logo

LEO Pharma·Phase 2·NCT05470114·13 enrolled

Immunotherapy1 trial

Grass Pollen Immunotherapy Plus Dupilumab for Tolerance Induction

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT04502966·108 enrolled

Chronic Rhinosinusitis With Nasal Polyposis1 trial

Assessing Long-Term Outcomes of DUPIXENT® Treatment in Patients With Chronic Rhinosinusitis With Nasal Polyposis (AROMA)

Active, not recruiting· Regeneron logo

Regeneron··NCT04959448·717 enrolled

Sources

References

[1]
ClinicalTrials.gov — 9 trial records for DUPIXENT. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — DUPIXENT compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for DUPIXENT. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Regeneron company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Regeneron

DUPIXENT

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Q2 2027

Q1 2028

Q2 2028

Trials by Indication[1]

Tics1 trial

Atopic Dermatitis1 trial

Phase II1 trial

Nasal Polyps1 trial

Asthma1 trial

MPA1 trial

Adult1 trial

Immunotherapy1 trial

Chronic Rhinosinusitis With Nasal Polyposis1 trial

References

Drug Info

Quick Facts

Related News